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Abstract  
Preeclampsia (PE) is a multisystem disorder of pregnancy and a major cause of maternal morbidity and mortality worldwide. 
The disease is recently attributed to maternal endothelial dysfunction. The quest for ideal biomarker goes on. Pregnancy-
associated plasma protein A (PAPP-A), Placental growth Factor (PLGF) and sFlt-1 (soluble fms-like tyrosine kinase-1) are 
the new biomarkers that hold promise for future. We present a short review on current biomarkers that would enable us to 
diagnose PE timely leading to reduced maternal morbidity and mortality , justifying the saying,  ‘ a stitch in time saves nine’. 
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Introduction 
The current decades have witnessed improved antenatal 
care but preeclampsia (PE)  poses a serious complication of 
second half of Pregnancy with a frequency of 5-10 %. It is a 
leading cause of maternal morbidity which can lead to 
maternal death, fetal growth retardation, infant morbidity and 
mortality (Hoffman et al., 2011). Preeclampsia is defined as a 
systolic blood pressure ≥ 140 mmHg or diastolic blood 
pressure ≥ 90 mmHg on 2 occasions at least 4 hrs apart after 
20weeks gestation in women with a previously normal blood 
pressure or ≥ 160 mmHg systolic or ≥ 110 mmHg diastolic, 
and proteinuria ≥ 300 mg/ 24hrs or a Protein / creatinine ratio 
≥ 0.3 mg/dl or a dipstick reading of ≥ 1+ (ACOG, 2013). 
The early diagnosis of PE remains a challenge to modern 
obstetrician due to lack of specific marker or single test that is 
sensitive and specific enough for identification of high risk 
pregnancies for PE. The pathogenesis of preeclampsia is 
unclear (Lorentzen and Henriksen, 1998). Trophoblast cells 
and an accelerated maternal systemic response to 
trophoblastic tissue are the core stone in pathogenesis of 
preeclampsia (Sargent et al., 2003; Roberts and Hubel, 2009). 
In early pregnancy abnormal placentation occurs which leads 
to placental ischemia (Stage I). The ischemic placenta is 
thought to secrete soluble factors during the third trimester 
that in turn induces systemic endothelial dysfunction and the 
maternal syndrome of preeclampsia (Stage II) (Redman and 
Sargent, 2005). In normal pregnancy there is trophoblastic 
invasion of the spiral arteries in the decidual and myometrial 
segments of the placental bed, whereas in preeclampsia such 
physiological adaptation does not occur severely 
compromising their ability to deliver maternal blood in the 
intervillous space.  The diagnosis of PE relies on medical and 
obstetrics history, markers like maternal Serum pregnancy 
associated Plasma protein –A (PAPP-A) and Placental growth 
Factor (PLGF) at 11-13 weeks, uterine artery pulsatility Index 
(PI) and Mean arterial Pressure (MAP) (Wright et al., 2012; 
Akolekar et al., 2013). In this article we focus on biomarkers 
for PE screening.  
Maternal serum PAPP-A and PlGF are two biochemical 
markers that have been investigated extensively and have 
shown promising results in the early prediction of PE at 11–13 
weeks’ gestation, and are done on automated machines that 
provide reproducible results within 30–40 min of sampling 
(Wright et al., 2014). Pregnancy-associated plasma protein A 
(PAPP-A) is a peptidase produced by syncitiotrophoblast with 
hydrolytic activity for insulin-like growth factor binding 
proteins (Kleinrouweler et al., 2012). These regulate insulin 
growth factors known to be important for implantation, for 
trophoblast invasion of maternal decidua and for placental 
growth. It is released into the maternal circulation where it 
binds the eosinophil major binding protein, an inhibitor of its 
proteolytic activity (Poon and Nicolaides, 2014). Decreased 
levels of PAPP-A in the first trimester have been associated 
with increased risk of adverse pregnancy outcomes, including 
preeclampsia. 
Serum levels of PGF and sFlt-1 (soluble fms-like tyrosine 
kinase-1, also known as soluble VEGF receptor-1) are altered 
in women with preeclampsia. Maternal serum levels of sFlt-1 
are higher and PGF lower in women presenting with 
preeclampsia. Soluble fms-like tyrosine kinase-1 (sFlt-1 or 
sVEGFR-1) is a tyrosine kinase protein with antiangiogenic 
properties. A non-membrane associated splice variant of 
VEGF receptor 1 (Flt-1), sFlt-1 binds the angiogenic factors 
VEGF (vascular endothelial growth factor) and PlGF 
(placental growth factor), reducing blood vessel growth 
through reduction of free VEGF and PlGF concentrations 
(Khalil et al., 2008). In humans, sFlt-1 is important in the 
regulation of blood vessel formation in diverse tissues, 
including the kidneys, cornea, and uterus (Ambati et al., 2006; 
Luft, 2014). Abnormally high levels of sFlt-1 have been 
implicated in the pathogenesis of preeclampsia (Maynard et 
al., 2003). In preeclamptic patients, this arterial transformation 
is incomplete, as cytotrophoblasts fail to completely switch 
their adhesion molecule expression pattern to an endothelial 
form. The balance of pro- and anti-angiogenic factors and 
their receptors, including VEGF-A, PIGF, Flt1, and sFlt1, is 
thought to mediate this process (Maynard et al., 2003). 
PlGF and sFlt-1 concentrations measured by 
immunoassay in maternal blood improve the prognostic 






possibilities in preeclampsia, which is typically diagnosed 
solely on the basis of clinical symptoms, proteinuria, and 
uterine artery Doppler velocimetry (Thadhani et al., 2004; 
Hirashima et al., 2005). Notably, increases in sFlt-1 and 
decreases in PIGF and VEGF can be detected at least five 
weeks before the onset of preeclamptic symptoms, potentially 
facilitating earlier diagnosis and treatment (Levine et al., 
2004). sFlt-1 elevation is also associated with other obstetric 
conditions such as non-preeclampsic interuterine growth 
retardation of the fetus, limiting its use as a discriminatory 
biomarker for preeclampsia (Bersinger et al., 2003). 
Additionally, sensitivity and specificity of sFlt-1 testing is 
generally considered too low to enable it to serve as an 
effective predictor of preeclampsia (Stepan et al., 2004). 
However, PE is associated with reduced PIGF production and 
these reduced levels precede the clinical onset of the disease 
and are evident from first and second trimester of pregnancy 
(Polliotti et al., 2003; Krauss et al., 2004; Erez et al., 2008; 
Crispi et al., 2008).. 
It is extremely important that while performing the 
biochemical assay appropriate adjustments for maternal age , 
pregnancy , instrument and reagent are made and the results 
expressed as multiple of the expected median (MoM) of the 
normal (Kagan et al., 2008). MoM values of PAPP-A and 
PIGF are reduced at 11-13 weeks in pregnancy associated 
with PE. Serum sFlt-1 increases with gestational age and 
maternal age and decreases with maternal weight; it is 
increased in women of Afro-Caribbean racial origin and in 
pregnancies conceived by IVF and is lower in parous than 
nulliparous women (Lai et al., 2014). 
Conclusion 
The screening for early onset of PE can be successfully 
done in first trimester pregnancy with the help of new 
biomarkers alongside the history and biophysical markers. 
This would enable detection of cases that require prophylactic 
intervention.  Prospective studies are underway to ascertain 
the predictive capabilities of these markers, till then the quest 
for single specific screening marker go on.  
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